Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

PURPOSE: Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). The primary objectives of this phase IIa study included safety at the recommended phase II dose...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rudin, Charles M., Hann, Christine L., Garon, Edward B., Ribeiro de Oliveira, Moacyr, Bonomi, Philip D., Camidge, D. Ross, Chu, Quincy, Giaccone, Giuseppe, Khaira, Divis, Ramalingam, Suresh S., Ranson, Malcolm R., Dive, Caroline, McKeegan, Evelyn M., Chyla, Brenda J., Dowell, Barry L., Chakravartty, Arunava, Nolan, Cathy E., Rudersdorf, Niki, Busman, Todd A., Mabry, Mack H., Krivoshik, Andrew P., Humerickhouse, Rod A., Shapiro, Geoffrey I., Gandhi, Leena
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3715059/
https://ncbi.nlm.nih.gov/pubmed/22496272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3090
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados